M28 Capital Management L.P. is an investment fund managing more than $95.8 million ran by Christopher Taliercio. There are currently 12 companies in Mr. Taliercio’s portfolio. The largest investments include Invivyd Inc and Wave Life Sciences, together worth $57.8 million.
As of 3rd November 2022, M28 Capital Management L.P.’s top holding is 9,248,250 shares of Invivyd Inc currently worth over $28.9 million and making up 30.2% of the portfolio value.
In addition, the fund holds 7,982,204 shares of Wave Life Sciences worth $28.8 million, whose value grew 143.2% in the past six months.
The third-largest holding is Rocket Pharmaceuticals Inc worth $10.6 million and the next is Stoke Therapeutics worth $6.71 million, with 522,550 shares owned.
Currently, M28 Capital Management L.P.'s portfolio is worth at least $95.8 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The M28 Capital Management L.P. office and employees reside in Stamford, Connecticut. According to the last 13-F report filed with the SEC, Christopher Taliercio serves as the President and Chief Compliance Officer at M28 Capital Management L.P..
In the most recent 13F filing, M28 Capital Management L.P. revealed that it had increased its stake in
Invivyd Inc and bought 2,850,000 additional shares worth around .
On the other hand, there are companies that M28 Capital Management L.P. is getting rid of from its portfolio.
M28 Capital Management L.P. closed its position in Atara Biotherapeutics Inc on 10th November 2022.
It sold the previously owned 389,353 shares for $3.62 million.
Christopher Taliercio also disclosed a decreased stake in Rocket Pharmaceuticals Inc by approximately 0.1%.
This leaves the value of the investment at $10.6 million and 665,880 shares.
The two most similar investment funds to M28 Capital Management L.P. are Tevis Investment Management and Schaller Investment Group Inc. They manage $95.8 million and $95.7 million respectively.
M28 Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 65.8% of
the total portfolio value.
The fund focuses on investments in the United States as
58.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
17% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $897 million.
These positions were updated on November 10th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Invivyd Inc |
44.54%
9,248,250
|
$28,947,000 | 30.22% |
| Wave Life Sciences Ltd. |
36.45%
7,982,204
|
$28,816,000 | 30.08% |
| Rocket Pharmaceuticals Inc |
6.98%
665,880
|
$10,627,000 | 11.09% |
| Stoke Therapeutics, Inc. |
0.87%
522,550
|
$6,710,000 | 7.00% |
| BridgeBio Pharma Inc |
10.10%
513,300
|
$5,102,000 | 5.33% |
| Mirati Therapeutics Inc |
26.18%
61,200
|
$4,274,000 | 4.46% |
| Atara Biotherapeutics Inc |
Closed
389,353
|
$3,617,000 | |
| Curis Inc |
5.63%
4,482,142
|
$3,137,000 | 3.27% |
| Verve Therapeutics Inc |
50.92%
87,600
|
$3,009,000 | 3.14% |
| Leap Therapeutics Inc |
No change
2,664,400
|
$2,345,000 | 2.45% |
| TG Therapeutics Inc |
67.67%
338,800
|
$2,006,000 | 2.09% |
| Proqr Thrapeutics N V |
No change
1,001,800
|
$745,000 | 0.78% |
| Neximmune Inc |
No change
133,442
|
$74,000 | 0.08% |
| No transactions found | |||
| Showing first 500 out of 13 holdings | |||